By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – OptiGene today announced an agreement to license Eiken Chemical's LAMP gene amplification technology.

Separately, Eiken this week said that it also is licensing the technology to the UK Veterinary Laboratories Agency.

As part of its agreement, OptiGene will develop, manufacture, and sell nucleic acid amplification reagents for research use.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.